Supernus Pharmaceuticals, Inc. (SUPN)Healthcare | Drug Manufacturers - Specialty & Generic | Rockville, United States | NasdaqGM
39.57 USD
-0.61
(-1.518%) ⇩
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:02 a.m. EDT
The investment case for Supernus hinges entirely on the turnaround story rather than current profitability. Fundamentally, the company shows strong signs of recovery with revenue growing 32% year-over-year and gross margins expanding to nearly 73%, suggesting the core business is stabilizing. However, the bottom line remains in the red with negative operating margins and a trailing P/E that is mathematically undefined due to losses, which caps the long-term rating at a solid 'buy' (3 stars) rather than an exceptional one. The balance sheet is healthy with minimal debt relative to cash, providing a safety net for R&D execution. Short-term, the outlook is mixed. The stock has recently rallied off multi-year lows, yet the statistical forecasting model offers almost no directional bias, and options flow reveals a distinct lack of bullish aggression. Traders are buying deep out-of-the-money puts, betting on a potential earnings miss or continued volatility, while call interest remains muted. This defensive positioning suggests the market is waiting for confirmation that the operational improvements will translate into sustainable earnings before committing capital. Until the company posts a profitable quarter, the short-term trend remains range-bound with a slight downside lean due to the hedging activity. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.089857 |
| AutoETS | 0.093704 |
| AutoARIMA | 0.093723 |
| AutoTheta | 0.095488 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 4.90 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.110 |
| Excess Kurtosis | 0.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.895 |
| Revenue per Share | 14.465 |
| Market Cap | 2,303,929,344 |
| Forward P/E | 9.19 |
| Beta | 0.55 |
| Profit Margins | -13.23% |
| Website | https://www.supernus.com |
As of Oct. 10, 2026, 9:02 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes significantly below the current price (e.g., $30, $35, $40), creating a substantial floor of downside protection. Conversely, call activity is sparse and concentrated near the money, indicating a lack of aggressive bullish conviction despite the stock trading near its 52-week lows. Implied volatility is elevated on near-term expirations, reflecting uncertainty around the upcoming earnings report.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.21128166 |
| Address1 | 9,715 Key West Avenue |
| All Time High | 61.25 |
| All Time Low | 4.3 |
| Ask | 56.0 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 870,680 |
| Average Daily Volume3 Month | 771,731 |
| Average Volume | 771,731 |
| Average Volume10Days | 870,680 |
| Beta | 0.554 |
| Bid | 33.83 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 17.73 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 39.57 |
| Current Ratio | 2.083 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 41.31 |
| Day Low | 39.36 |
| Debt To Equity | 3.895 |
| Display Name | Supernus Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,760,200 |
| Earnings Call Timestamp Start | 1,785,760,200 |
| Earnings Timestamp | 1,785,760,200 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | 110,432,000 |
| Ebitda Margins | 0.13298 |
| Enterprise To Ebitda | 17.823 |
| Enterprise To Revenue | 2.37 |
| Enterprise Value | 1,968,188,928 |
| Eps Current Year | 2.535 |
| Eps Forward | 4.305 |
| Eps Trailing Twelve Months | -1.92 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 44.0098 |
| Fifty Day Average Change | -4.4398003 |
| Fifty Day Average Change Percent | -0.10088208 |
| Fifty Two Week Change Percent | -21.128166 |
| Fifty Two Week High | 59.68 |
| Fifty Two Week High Change | -20.11 |
| Fifty Two Week High Change Percent | -0.3369638 |
| Fifty Two Week Low | 39.36 |
| Fifty Two Week Low Change | 0.20999908 |
| Fifty Two Week Low Change Percent | 0.0053353426 |
| Fifty Two Week Range | 39.36 - 59.68 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,335,879,000,000 |
| Float Shares | 51,744,667 |
| Forward Eps | 4.305 |
| Forward P E | 9.191638 |
| Free Cashflow | 84,611,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 778 |
| Fullday Change | -0.6100006 |
| Fullday Change Percent | -1.5181698 |
| Fullday Price | 39.57 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.72890997 |
| Gross Profits | 605,312,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04322 |
| Held Percent Institutions | 1.05965 |
| Implied Shares Outstanding | 58,224,143 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland. |
| Long Name | Supernus Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 2,303,929,344 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_422832 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -109,886,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,525,181,081 |
| Number Of Analyst Opinions | 4 |
| Open | 40.21 |
| Operating Cashflow | 19,911,000 |
| Operating Margins | -0.02485 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 301 838 2500 |
| Previous Close | 40.18 |
| Price Eps Current Year | 15.609467 |
| Price Hint | 2 |
| Price To Book | 2.2318106 |
| Price To Sales Trailing12 Months | 2.7743545 |
| Profit Margins | -0.13232 |
| Quick Ratio | 1.68 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.610001 |
| Regular Market Change Percent | -1.51817 |
| Regular Market Day High | 41.31 |
| Regular Market Day Low | 39.36 |
| Regular Market Day Range | 39.36 - 41.31 |
| Regular Market Open | 40.21 |
| Regular Market Previous Close | 40.18 |
| Regular Market Price | 39.57 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 911,518 |
| Return On Assets | 0.0038800002 |
| Return On Equity | -0.104899995 |
| Revenue Growth | 0.324 |
| Revenue Per Share | 14.465 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 58,224,143 |
| Shares Percent Shares Out | 0.0856 |
| Shares Short | 4,985,929 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,671,860 |
| Short Name | Supernus Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.104899995 |
| Short Ratio | 7.89 |
| Source Interval | 15 |
| State | MD |
| Symbol | SUPN |
| Target High Price | 67.0 |
| Target Low Price | 55.0 |
| Target Mean Price | 60.5 |
| Target Median Price | 60.0 |
| Total Cash | 372,067,008 |
| Total Cash Per Share | 6.401 |
| Total Debt | 40,170,000 |
| Total Revenue | 830,438,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.92 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 47.8187 |
| Two Hundred Day Average Change | -8.248699 |
| Two Hundred Day Average Change Percent | -0.17249945 |
| Type Disp | Equity |
| Volume | 911,518 |
| Website | https://www.supernus.com |
| Zip | 20,850 |